Fahad Alabbas,Talal Alanzi,Abdulrahman Alrasheed,Mohammed Essa,Ghaleb Elyamany,Abdulrahman Asiri,Sajdi Almutairi,Sulaiman Al-Mayouf,Abdullatif Alenazi,Danyah Alsafadi,Walid Ballourah,Naif Albalawi,Ehab Hanafy,Abdulqader Al-Hebshi,Seham Alrashidi,Fatma Albatniji,Huda Alfaraidi,Tahani Bin Ali,Mansour Al Qwaiee,Maryam AlHilali,Hayam Aldeeb,Ali Alhaidey,Hassan Aljasem,Sami Althubaiti,Abdulrahman Alsultan

Abstract:Adenosine deaminase 2 deficiency (DADA2), a rare and potentially fatal systemic autoinflammatory disease, is characterized by low or lack of ADA2 activity due to ADA2 mutations. DADA2 symptoms are variable and include vasculitis, immunodeficiency, and cytopenia. Minimal data are available from Saudi Arabia. This retrospective study conducted at seven major tertiary medical centers examined the phenotypic and genotypic variabilities, clinical and diagnostic findings, and treatment outcomes among 20 Saudi patients with DADA2 from 14 families. The median age of the study cohort was 9.5 years (4-26 years). The clinical presentation was before the age of 5 months in 25% of patients. Homozygous c.1447-1451del mutation was the most frequent ADA2 alteration (40%), followed by c.882-2A:G (30%). All tested patients exhibited absent or near-absent ADA2 activity. Phenotypic manifestations included stroke (40%), hematological abnormalities (95%), lymphoproliferation (65%), and recurrent infection (45%). Five and three patients had extracranial vasculitis features and Hodgkin lymphoma, respectively. Atypical manifestations included growth retardation (30%) and transverse myelitis. Anti-tumor necrosis factor (anti-TNF) therapy was the main treatment. Some patients underwent blood transfusion, splenectomy, cyclosporine and colony-stimulating factor therapies, and hematopoietic stem cell transplantation due to anti-TNF therapy failure. Fulminant hepatitis and septic multiorgan failure caused mortality in three patients. Thus, this study revealed the variability in the molecular and clinical characteristics of DADA2 in the study cohort with predominant aberrant hematological and immunological characteristics. Consensus diagnostic criteria will facilitate early diagnosis and treatment. Additionally, disease registries or large prospective studies are needed for evaluating rare disease complications, such as cancer.

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity

Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2).

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort

Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance

Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India

Alcohol as a Gastric Disinfectant? The Complex Relationship between Alcohol Consumption and Current Helicobacter pylori Infection

Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease with Severe Consequences

Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2

Evaluation and Management of Deficiency of Adenosine Deaminase 2: an International Consensus Statement.

Human ADA2 deficiency is characterized by the absence of an intracellular hypoglycosylated form of adenosine deaminase 2

A case report on deficiency of adenosine deaminase 2 with relapse–remission course and analysis of genotype–phenotype correlation

A Cohort Study on Deficiency of ADA2 from China

Detrimental Effects of Adenosine Signaling in Sickle Cell Disease

Deficiency of adenosine deaminase 2 (DADA2) with bilateral renal subcapsular hematoma: a case report and literature review

Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2)

Genotype and Phenotype of Adenosine Deaminase 2 Deficiency: a Report from Saudi Arabia

Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients

ADA2 Deficiency (DADA2) As an Unrecognised Cause of Early Onset Polyarteritis Nodosa and Stroke: a Multicentre National Study

Human ADA2 Deficiency: Ten Years Later

A Narrative Review of the Neurological Manifestations of Human Adenosine Deaminase 2 Deficiency